Physician profile
Meetu Agrawal
NPI 1679821458
$9,776.52
in general payments reported to CMS, 2019-2025
30 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $603 · 2021: $1,295 · 2022: $1,737 · 2023: $1,927 · 2024: $1,151 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,973.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,753.11 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,244.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $771.41 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $700.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $521.75 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $500.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $320.73 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $274.81 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.70 | 2019-2025 | Jardiance, Tradjenta |
| Vanda Pharmaceuticals INC. | $239.61 | 2019-2023 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $216.06 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $187.85 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $130.71 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.69 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $80.48 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $70.07 | 2023-2024 | Quviviq |
| Horizon Therapeutics Plc | $59.97 | 2020-2021 | |
| Astellas Pharma US INC | $59.44 | 2024-2025 | Veozah |
| Dexcom, INC. | $57.32 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $47.33 | 2025 | Korlym |
| Gilead Sciences, INC. | $46.34 | 2025 | |
| Allergan, INC. | $42.67 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $30.50 | 2022 | |
| Dynavax Technologies Corporation | $27.66 | 2025 | Heplisav-B |
| Irhythm Technologies, INC. | $23.56 | 2024 | Zio Monitor, Zio Xt Patch |
| Novartis Pharmaceuticals Corporation | $18.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.14 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.74 | 2025 | Nuzyra |
| Eisai INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meetu Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.